Fig. 1

AZD1775 reduces cell viability and promotes apoptosis in a p53-independent manner in ALL cell lines. A Dose–response curves of ALL cell lines to AZD1775 for 96 h. Growth inhibitions were measured using a resazurin-based assay. Data were normalized to DMSO control and represent mean ± SEM of three independent experiments. B Immunoblot of p53 protein levels in the NALM6 TP53 isogenic lines. C Dose–response curves of the NALM6 TP53 isogenic lines to AZD1775 for 96 h. Data were normalized to DMSO control and represent mean ± SEM of three independent experiments. D Evaluation of apoptosis by Annexin-V staining in the NALM6 TP53 isogenic lines treated with DMSO or 200 nM AZD1775 for 24–48 h. Error bars indicate mean ± SD of three independent experiments. E Immunoblot of apoptotic marker cleaved PARP (Asp214) in NALM6 cells treated for 24 h with DMSO or increasing doses of AZD1775. F Immunoblot of cell cycle markers in NALM6 cells treated for 6 h with DMSO or increasing doses of AZD1775. In B, E, and F, ɑ-tubulin was used as loading control and images are representative of three independent experiments